Statins are well-known
cholesterol lowering drugs targeting
HMG-CoA-reductase, reducing the risk of coronary disorders and
hypercholesterolemia.
Statins are also involved in
immunomodulation, which might influence the outcome of
bacterial infection. Hence, a possible effect of
statin treatment on
Listeriosis was explored in mice.
Statin treatment prior to subsequent L. monocytogenes
infection strikingly reduced bacterial burden in liver and spleen (up to 100-fold) and reduced histopathological lesions.
Statin-treatment in infected macrophages resulted in increased
IL-12p40 and TNF-α and up to 4-fold reduced bacterial burden within 6 hours post
infection, demonstrating a direct effect of
statins on limiting bacterial growth in macrophages. Bacterial uptake was normal investigated in
microbeads and GFP-expressing Listeria experiments by confocal microscopy. However, intracellular membrane-bound
cholesterol level was decreased, as analyzed by
cholesterol-dependent
filipin staining and cellular
lipid extraction.
Mevalonate supplementation restored
statin-inhibited
cholesterol biosynthesis and reverted bacterial growth in Listeria monocytogenes but not in
listeriolysin O (LLO)-deficient Listeria. Together, these results suggest that
statin pretreatment increases protection against L. monocytogenes
infection by reducing membrane
cholesterol in macrophages and thereby preventing effectivity of the
cholesterol-dependent LLO-mediated phagosomal escape of bacteria.